Corbus Pharmaceuticals receives U.S. patent for Anabasum in Treatment of Rare Fibrotic Diseases
Norwood, Massachusetts-based Corbus Pharmaceuticals (NASDAQ: CRBP), a Phase 3 clinical stage drug development company targeting rare, chronic, inflammatory and fibrotic diseases, announced today that the U.S. Patent and Trademark Office issued it a patent for pharmaceuticals containing Anabasum. The patent covers treatment of fibriotic diseases including systemic sclerosis, dermatomyositis, cystic fibrosis and others. The patent gives Corbus intellectual property protection in the US for anabasum through 2034.
In a day when many cannabis stocks fell as investors took profits, Corbus stock rose 7% on the patent news to close at $7.65.
Corbus recently received a patent covering anabasum use for inflammatory diseases such as systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, psoriasis and others.
Anabasum, the company’s lead product candidate, is a synthetic oral endocannabinoid-mimetic drug candidate designed to treat chronic inflammation and fibrosis. It triggers physiologic pathways that resolve inflammation, speed bacterial clearance and halt fibrosis. Nonclinical and human clinical studies have shown anabasum has favorable safety, tolerability and pharmacokinetic profiles.
The Company expects to begin a Phase 2 study of anabasum for systemic lupus erythematosus, a Phase 3 study for systemic sclerosis and a Phase 2b study for cystic fibrosis in the fourth quarter of 2017.
Source: Corbus press release
Corbus Pharmaceuticals receives U.S. patent for Anabasum in Treatment of Rare Fibrotic Diseases
About Cannin Investment Group: Your Pot Stocks Experts
Cannin is your trusted resource for pot stocks. Our global team of experts evaluates all emerging pot stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best pot stock investments for 2020.
Use Cannin as your resource for:
- Cannabis and hemp investing news
- Featured cannabis and hemp company analysis
- Comprehensive cannabis and hemp stock reports
Is it too late to invest in pot stocks? No! This is the perfect time to invest.
Market analysts expect the legal cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in pot stocks is now. Are you looking to buy stock in pot companies for 2020? Interested in emerging penny pot stocks? Looking for the best Canadian pot stocks to invest in? We can help.
Are you interested in pot stocks like Curaleaf, Trulieve, Aurora Cannabis, or Canopy Growth?
Predict price movements of pot stocks several hours in advance with our proprietary algorithmic stock trading software.
- +25% Gains in 2020
- +49.8% Gains in 2019
- 108% Backtested since 2012
We’re so confident you’ll love our algotrading pot stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.
Profit from the best pot stocks – we’ll show you how at cannin.com.
Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Penny Hemp Stocks
